Roche Warns Of Bigger Negative Impact From COVID-19 And Biosimilars
Executive Summary
Biosimilar competitors to Avastin, Herceptin and Rituxan and headwinds from COVID-19 are expected to have a CHF4.7bn negative impact in 2020, higher than the CHF4bn previously projected.
You may also be interested in...
Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology
Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy.
US Biosimilar Spending Poised For Substantial Growth By 2024, IQVIA Says
Biosimilar spending in the US is expected to increase from $5.2bn in 2019 to $27bn in 2024, driven by increased penetration and new biosimilar entries, including for Humira, according to an IQVIA report.
Stockwatch: Full-Year 2020 Guidance Separates Novartis And Roche
Pandemic-related clinic closures and safety issues forced Novartis to trim its guidance slightly. But Roche, faced with more severe pandemic and biosimilar pressures, left January’s guidance unchanged.